摘要
目的对糖尿病视网膜病变伴随黄斑水肿患者应用玻璃体腔注射雷珠单抗治疗效果进行深入分析。方法选取2021年1月—2023年1月甘肃省甘南藏族自治州人民医院60例糖尿病视网膜病变伴随黄斑水肿患者为研究对象,应用抽样法分组,分为常规治疗的参照组和玻璃体腔注射雷珠单抗治疗的研究组,每组各30例,研究两组的临床指标优良度。结果治疗前,两组的CMT大致相同,差异无统计学意义(P>0.05);治疗后1、3个月,研究组的CMT低于参照组,差异有统计学意义(P<0.05)。治疗前,两组的BCVA大致相同,差异无统计学意义(P>0.05);治疗后1、3个月,研究组的BCVA低于参照组,差异有统计学意义(P<0.05)。研究组的并发症发生率低于参照组,差异有统计学意义(P<0.05)。研究组的水肿消退率高于参照组,差异有统计学意义(P<0.05)。结论应用玻璃体腔注射雷珠单抗治疗,可改善患者的视力功能,缓解其黄斑水肿症状,值得应用。
Objective To analyze the therapeutic effect of vitreous cavity injection of Ranibizumab in patients with diabetic retinopathy with macular edema.Methods From January 2021 to January 2023,60 patients with Diabetic retinopathy accompanied by Macular edema in the Gannan Tibetan Autonomous Prefecture People's Hospital in Gansu Province were selected as the research objects.The sampling method was applied to group them into the reference group of conventional treatment and the study group of vitreous cavity injection of Ranibizumab treatment,30 cases in each group,and the excellent clinical indexes of the two groups were studied.Results Before treatment,the CMT of the two groups were roughly the same,and the difference was not statistically significant(P>0.05).After 1 and 3 months of treatment,the CMT of the study group was lower than that of the control group,and the difference was statistically significant(P<0.05).Before treatment,the BCVA of the two groups were roughly the same,and the difference was not statistically significant(P>0.05).After 1 and 3 months of treatment,the BCVA of the study group was lower than that of the reference group,and the difference was statistically significant(P<0.05).The incidence of complications in the study group were lower than that in the reference group,and the difference was statistically significant(P<0.05).The edema regression rate of the study group was higher than that of the reference group,and the difference was statistically significant(P<0.05).Conclusion The application of vitreous cavity injection of ranibizumab treatment can improve the visual function of patients and alleviate their macular edema symptoms,which is worthy of application.
作者
董玉成
陈朝晖
任娅丽
DONG Yucheng;CHEN Zhaohui;REN Yali(Ophthalmology Department,Gannan Tibetan Autonomous Prefecture People's Hospital,Gannan Tibetan Autonomous Prefecture,Gansu Province,747000 China)
出处
《糖尿病新世界》
2023年第12期25-28,共4页
Diabetes New World Magazine
